Skip to content
Study details
Enrolling now

Noninvasive Vagal Nerve Stimulation Trial

NYU Langone Health
NCT IDNCT06816004ClinicalTrials.gov data as of Apr 2026
Target enrollment

30

Study length

about 9 months

Ages

25–65

Locations

1 site in NY

About this study

This trial is testing whether remotely supervised transcutaneous auricular vagus nerve stimulation (taVNS), transcutaneous cervical vagus nerve stimulation (tcVNS), or transcranial direct current stimulation (tDCS) can help reduce symptoms in people with multiple sclerosis. The goal of this pilot trial is to determine if these treatments are feasible and may improve symptom reduction, as measured by self-reported outcomes and heart rate variability.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Use Remotely Supervised Transcranial Direct Current Stimulation (RS - tDCS)
  • 2.Use Remotely Supervised Transcutaneous Auricular Vagus Nerve Stimulation (RS - taVNS)
  • 3.Use Remotely Supervised Transcutaneous Cervical Vagus Nerve Stimulation (RS - tcVNS)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low9%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Secondary: Change in Composite Autonomic Symptom Score-31 (COMPASS-31) Score, Change in General Anxiety Disorder (GAD-7) Score, Change in Heart Rate Variability (HRV), Change in Memorial Symptom Assessment Scale (MSAS) Score, Change in PROMIS Fatigue - Short Form 7a Score, Change in PROMIS Pain Intensity - Short Form 3a Score, Change in Patient Health Questionnaire (PHQ-9) Score, Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form Score

Devices

therapeutic

Body systems

Neurology